1. DARS-AS1 Knockdown Inhibits the Growth of Cervical Cancer Cells via Downregulating HMGB1 via Sponging miR-188-5p
   Jinming Zhu et al, 2020, Technology in Cancer Research & Treatment CrossRef
2. Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer
   Franziska Böttger et al, 2024, Molecular Oncology CrossRef
3. Subcellular localization of HMGB1 in colorectal cancer impacts on tumor grade and survival prognosis
   Chao-Qun Wang et al, 2020, Scientific Reports CrossRef
4. LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis
   Yanjie Liu et al, 2020, Cancer Cell International CrossRef
5. Matrine exerts antitumor activity in cervical cancer by protective autophagy via the Akt/mTOR pathway in vitro and in vivo
   Fan Zhang et al, 2022, Oncology Letters CrossRef
6. Necrosis of osteosarcoma cells induces the production and release of high‑mobility group box 1 protein
   Jiyu Yang et al, 2017, Experimental and Therapeutic Medicine CrossRef
7. Long noncoding RNAs as biotargets in cisplatin-based drug resistance
   Nadiah Abu et al, 2018, Future Oncology CrossRef
8. Ethyl pyruvate protects against Salmonella intestinal infection in mice through down-regulation of pro-inflammatory factors and inhibition of TLR4/MAPK pathway
   Na Dong et al, 2019, International Immunopharmacology CrossRef
9. The multifaceted role of autophagy in cancer and the microenvironment
   Hendrik Folkerts et al, 2019, Medicinal Research Reviews CrossRef
10. Advances in research on autophagy mechanisms in resistance to endometrial cancer treatment
    Jingjing Ji et al, 2024, Frontiers in Oncology CrossRef
11. The Multidirectional Effect of Azelastine Hydrochloride on Cervical Cancer Cells
    Ewa Trybus et al, 2022, International Journal of Molecular Sciences CrossRef
12. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy
    Lin Run et al, 2021, Endocrine CrossRef
13. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential
    Reem Saleh et al, 2020, Expert Opinion on Therapeutic Targets CrossRef
14. Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer
    Xinjie Lu, 2022, Current Medicinal Chemistry CrossRef
15. Mechanistic insights into dimethyl cardamonin-mediated pharmacological effects: A double control of the AMPK-HMGB1 signaling axis
    Christian Bailly et al, 2020, Life Sciences CrossRef
16. Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression
    Nadia Hindi et al, 2023, International Journal of Molecular Sciences CrossRef
17. miR‑142‑3p reduces the viability of human cervical cancer cells by negatively regulating the cytoplasmic localization of HMGB1
    Hui Dong et al, 2021, Experimental and Therapeutic Medicine CrossRef
18. Interference with SMO increases chemotherapy drug sensitivity of A2780/DDP cells by inhibiting the Hh/Gli signaling pathway
    Shihong Ma et al, 2020, Journal of Cellular Biochemistry CrossRef
19. Tim-3 finds its place in the cancer immunotherapy landscape
    Nandini Acharya et al, 2020, Journal for ImmunoTherapy of Cancer CrossRef
20. Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma
    Brady Anderson et al, 2021, Onco CrossRef
21. HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression
    Xiu Lei et al, 2020, Cellular Signalling CrossRef
22. Other Immune Checkpoint Targets of Interest
    Clifford M. Csizmar et al, 2024, Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice CrossRef